On August 12, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, reported a conference call and webcast presentation regarding its recent directed share issue generating gross proceeds of USD 65 million (approximately SEK 567 million) (Press release, Saniona, AUG 12, 2020, View Source [SID1234563523]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will take place on Friday August 14th at 2 p.m. CET and will feature a presentation by Saniona’s management team to discuss the strategy and rationale for the financing, as well as an update on Saniona’s advancement of its late-stage clinical trials with Tesomet in two rare eating disorders, hypothalamic obesity (HO) and Prader Willi Syndrome (PWS), as well as progress building its U.S.-based organization in support of these programs.
Event number: 137 140 9570
Please add your questions in the Q&A field during the presentation.
If you prefer not to download the Webex app, please use the link temporary application to join the event.
AUDIO DETAILS
US: +1 408 758 98 56 Global call-in numbers
Event number: 137 140 9570
For those who are unable to listen at this time, a replay of the call will be available after the event through the investor section of Saniona’s web site at View Source